Read on Twitter
COMMENT: I was startled by the decision to delay the second dose of the Pfizer vaccine, mentioned at today’s morning presser which focused mainly on the Astra/Ox vaccine.
In the Phase 3 published on Dec 10th (Pfizer BioNTech), Table S5 looks at development of severe COVID after the first dose, up to and around the second.
Vaccine Efficacy (VE) for this parameter looks good, despite small groups so early in the trial.
Vaccine Efficacy (VE) for this parameter looks good, despite small groups so early in the trial.
Is this the basis for the decision?
Seems like an argument to delay the second dose?
Am I out of line? Crazy?
Good old fashioned wrong?
Seems like an argument to delay the second dose?
Am I out of line? Crazy?
Good old fashioned wrong?
Here the links...
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=recirc_mostViewed_railB_article
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_file/nejmoa2034577_appendix.pdf
https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=recirc_mostViewed_railB_article
https://www.nejm.org/doi/suppl/10.1056/NEJMoa2034577/suppl_file/nejmoa2034577_appendix.pdf
A fair point, but this data is all participants, from 18 years and upward. However, combined with the less COVID over the same period...
I'm still trending to not deviating from the protocol, despite trying to see the bright side... https://twitter.com/viropractor/status/1344354324814696450?s=20
I'm still trending to not deviating from the protocol, despite trying to see the bright side... https://twitter.com/viropractor/status/1344354324814696450?s=20
Another opinion on the topic.... https://twitter.com/PaulBieniasz/status/1344351940730347522?s=20
